RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3)

Clinical trials for RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3) explained in plain language.

Never miss a new study

Get alerted when new RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3) trials appear

Sign up with your email to follow new studies for RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New hope for kids with tough cancers: experimental drug trial opens

Disease control Recruiting now

This early-stage study is testing whether an experimental drug called codrituzumab is safe for children and young adults with solid tumors that have returned or stopped responding to standard treatments. The trial will enroll up to 50 participants aged 1 to 21 years whose tumors …

Matched conditions: RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3)

Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Apr 04, 2026 00:19 UTC

RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3)

Get alerted when new RECURRENT OR REFRACTORY GLYPICAN 3 (GPC3) trials appear

New hope for kids with tough cancers: experimental drug trial opens